Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments

Figures

• 

  Fig. 1. Mean changes from baseline in POA (a) and COA (b) scores. Subgroups were defined using the median POA and COA scores at baseline. For interaction analyses, §significance at the 0.1 level. *P<0.05; **P<0.01; ***P<0.001 for levomilnacipran ER versus placebo for score changes. COA, Continuity of Attention; ER, extended-release; ITT, intent-to-treat; n, number of patients with available assessments at baseline and end of treatment; LS, least squares; LSMD, least-squares mean difference between treatment groups; ns, not significant; POA, Power of Attention.

• 

  Fig. 2. Mean changes from baseline in MADRS (a) and SDS (b) total scores. Subgroups were defined using the median POA and COA scores at baseline. *P<0.05; **P<0.01; ***P=0.001 for levomilnacipran ER versus placebo for score changes. COA, Continuity of Attention; ER, extended-release; ITT, intent-to-treat; LS, least squares; LSMD, least-squares mean difference between treatment groups; MADRS, Montgomery–Åsberg Depression Rating Scale; n, number of patients with available assessments at baseline and end of treatment; ns, not significant; POA, Power of Attention; SDS, Sheehan Disability Scale.

• 

  Fig. 3. Mean changes from baseline in SDS subscale (a–c) scores. Subgroups were defined using the median POA and COA scores at baseline. For interaction analyses, §significance at the 0.1 level. *P<0.05; **P<0.01; ***P<0.001 for levomilnacipran ER versus placebo. COA, Continuity of Attention; ER, extended-release; ITT, intent-to-treat; LSM, least-squares mean; LSMD, least-squares mean difference between treatment groups; n, number of patients with available assessments at baseline and end of treatment; ns, not significant; POA, Power of Attention; SDS, Sheehan Disability Scale.